



Figure S8: Venn diagrams of numbers of individual KO markers (A) or pathways (B) for which their genomic density is positively or negatively correlated with CUE. In all instances, “glucose explore” is considered to consist of the proposed markers of efficiency, while the remaining three datasets are considered as “validating” datasets. Sample sizes (number of isolates or microcosms) for each analysis are as follows: other substrates (10-13); glucose explore (13); glucose all (22); microcosms (10).